Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of August 2026. The report discloses the issuance of a press release on August 31, 2026, announcing the completion of patient enrollment in the Company's multicenter IMPACT Pancreatic Cancer Pilot Study for its Alpha DaRT® technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone rather than financial performance.
Material Changes
The primary material event reported is the successful completion of patient enrollment in the IMPACT Pancreatic Cancer Pilot Study. The press release attributes this achievement to strong demand and multiple expansions of the study.
Outlook and Management Commentary
Management commentary is limited to the announcement of the enrollment milestone. The filing does not contain specific financial guidance, risk factors, contingencies, or unusual items beyond the context of the clinical trial progress.
Investor Verification Points
- Verify the specific details of the IMPACT Pancreatic Cancer Pilot Study design and endpoints.
- Confirm the timeline for the next phase of the study or data readout following enrollment completion.
- Review the attached Exhibit 99.1 (Press Release) for further details on the "strong demand" and "multiple expansions" mentioned.